Rethinking Treatment Goals in Psoriasis: Leveraging IL-17 Inhibitors to Move Beyond Skin Clearance Toward PsA Prevention - Episode 5
Exploring Evidence for Early Systemic Treatment to Prevent PsA
In this discussion, the panelists examine current evidence supporting early systemic treatment in psoriasis to help prevent psoriatic arthritis (PsA). The experts reference retrospective and observational studies suggesting that biologic therapies—particularly IL-17 and IL-23 inhibitors—may reduce the incidence of PsA development among patients with psoriasis. While acknowledging limitations in available data, such as the lack of prospective randomized trials, the panelists agree that existing evidence is meaningful and should inform proactive management. They stress that early initiation of systemic therapy can address the shared inflammatory pathways of skin and joint disease, potentially modifying disease progression before irreversible joint damage occurs. The experts highlight the importance of shifting from reactive to preventive care, emphasizing that treating psoriasis systemically and earlier in its course could close the current gap between achieving complete skin clearance and preventing long-term musculoskeletal complications.
In this discussion, the panelists examine current evidence supporting early systemic treatment in psoriasis to help prevent psoriatic arthritis (PsA). The experts reference retrospective and observational studies suggesting that biologic therapies—particularly IL-17 and IL-23 inhibitors—may reduce the incidence of PsA development among patients with psoriasis. While acknowledging limitations in available data, such as the lack of prospective randomized trials, the panelists agree that existing evidence is meaningful and should inform proactive management. They stress that early initiation of systemic therapy can address the shared inflammatory pathways of skin and joint disease, potentially modifying disease progression before irreversible joint damage occurs. The experts highlight the importance of shifting from reactive to preventive care, emphasizing that treating psoriasis systemically and earlier in its course could close the current gap between achieving complete skin clearance and preventing long-term musculoskeletal complications.
